Optibrium and The Edge collaborate to integrate StarDrop with BioRails platforms
![](/46/pdcnewsitem/04/28/85/Optibrium.png)
Combination provides an enterprise platform for comprehensive data management, analysis and compound design in drug discovery.
Optibrium and The Edge Software Consultancy have announced a collaboration to provide an integrated solution linking the StarDrop and BioRails platforms. The combination provides a seamless drug discovery workflow linking the latest research data directly from the lab through to decision making regarding the next round of synthesis and testing, reducing the time and cost to identify new optimisation strategies and target high quality compounds.
BioRails enables organisations to optimise the generation of high quality biological results stored in a dedicated data mart. The seamless link with StarDrop’s comprehensive capabilities for compound design, optimisation and data analysis ensures that project teams have instant access to the latest data on their compounds and can use them effectively, leading to better decisions and shorter project timelines.
The BioRails platform is designed to address a range of workflow driven research activities. BioRails can be used to design flexible processes and workflows for capturing experimental data, defining the procedures used to reliably capture high quality information. By separating design from execution BioRails provides separation between the plan and reality. This allows scientists to use the system across the full range of scientific investigations from routine activities such as ADME to more exploratory research such as in vivo behavioural studies.
Researchers can now seamlessly retrieve their biological results from BioRails using an intuitive, drag-and-drop search interface within StarDrop that enables users to easily create, share and execute database queries. StarDrop provides a highly visual way to interpret these data and their relationships with compound structures, clearly highlighting the best chemistries and multi-parameter optimisation strategies for drug discovery.
Dr Matthew Segall, CEO of Optibrium, commented: “We are delighted to be working with The Edge to provide integrated solutions to our mutual customers. We know that gaining convenient access to the latest data and using them to make good optimisation decisions is a challenge, particularly in smaller organisations without an established informatics infrastructure, and this collaboration enables us to provide a complete solution to their needs.”
“We were impressed with the design elements of Optibrium’s solutions, which rely on access to high quality results. The complimentary aspects of our solutions were clear and our experience of working together to the benefit of our customers has been very positive. We look forward to bringing this capability to many more organisations, large and small”, said Dr Andrew Lemon, The Edge’s CEO.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance